Riskpilot← Back to searchSign inGet full accessCytokin Holding AB
ABIn liquidationOrg 5568559347General medical practice activities · NACE 8621Est. 20110 employees
Revenue 2019
SEK 145K
-80% vs 2018
EBITDA margin
-126.2%
-135% vs 2018
Equity ratio
8.0%
Financial strength
Net profit 2019
SEK -2,7M
-117% vs 2018
| Revenue | SEK 145K | -80% |
| EBITDA | SEK -183K | -135% |
| Net profit | SEK -2,7M | -117% |
| Total assets | SEK 1,2M | -98% |
| Equity | SEK 94K | -100% |
| Employees | 0 | — |
Legal name
Cytokin Holding AB
Org number
5568559347
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
15 juni 2011
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Company purpose
Aktiebolaget ska bedriva läkarkonsultverksamhet inom mediciniskt etablerad vetenskap samt handel med värdepapper och fastigheter, konst och antikviteter samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Revenue | — | 0 | 158 | 724 | 145 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | −682 | −47 | 517 | −183 |
| Depreciation & amort. | −0 | −139 | −0 | −0 | −0 |
| EBIT | 0 | −821 | −47 | 517 | −183 |
| Net financials | 10 727 | 13 288 | 8 463 | 15 508 | −2 451 |
| Profit before tax | 10 727 | 12 535 | 8 417 | 16 025 | −2 634 |
| Tax | −0 | −482 | −239 | −397 | −47 |
| Net profit | 10 727 | 12 053 | 8 178 | 15 628 | −2 681 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Total assets | 10 807 | 33 783 | 41 339 | 56 836 | 1 173 |
| Equity | 10 802 | 32 820 | 40 833 | 56 297 | 94 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 | 963 | 505 | 539 | 1 079 |
| Total debt | 5 | 963 | 505 | 539 | 1 079 |
EBITDA margin
-126.2%
This company
15.8%
Market median
-899% vs market
20152019
Equity ratio
8.0%
This company
38.2%
Market median
-79% vs market
20152019
Return on equity
-2852.1%
This company
18.4%
Market median
-15601% vs market
20152019
Net profit margin
-1849.0%
This company
8.1%
Market median
-22927% vs market
20152019
Asset turnover
0.12×
This company
1.12×
Market median
-89% vs market
20152019
Debt / equity
11.48×
This company
0.62×
Market median
-1752% vs market
20152019
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
LM Authorized Recipient of Service | Authorized Recipient of Service | 2020 – 2020 |
JF Liquidator | Liquidator | 2020 – 2022 |
PM Chief Auditor | Chief Auditor | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Deputy Board Member | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cytokin Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lovisa Maj Anna Marie Haeger | Authorized Recipient of Service | 0 companies |
| Johan Fredrik Ståhl | Liquidator | 0 companies |
| Per Markus Hellsten | Chief Auditor | 0 companies |
| Marit Sofia Kristina Vesterlund | Deputy Board Member | 0 companies |
| Per Magnus Agnar Haeger | Board of Directors | 0 companies |